Article info
PDFHepatology
Original article
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
- Correspondence to Professor Chun-Ying Wu, Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 155, Sec. 2, Linong Street, Taipei 112, Taiwan; chun{at}vghtc.gov.tw
Citation
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Publication history
- Revised May 16, 2012
- Accepted May 18, 2012
- First published July 7, 2012.
Online issue publication
February 09, 2017
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data Supplement 1 - Online Supplement Figure 1
- Data Supplement 2 - Online Supplement Figure 2
- Data Supplement 3 - Online Supplement Figure 3
- Data Supplement 4 - Online Supplement Figure 4
- Data Supplement 5 - Online Supplement Figure 5
- Data Supplement 6 - Online Supplement Figure 6
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions